keyword
https://read.qxmd.com/read/25452859/retinopathy-and-clinical-outcomes-in-patients-with-type-2-diabetes-mellitus-chronic-kidney-disease-and-anemia
#21
JOURNAL ARTICLE
Natalie A Bello, Marc A Pfeffer, Hicham Skali, Janet B McGill, Jerome Rossert, Kurt A Olson, Larry Weinrauch, Mark E Cooper, Dick de Zeeuw, Peter Rossing, John J V McMurray, Scott D Solomon
OBJECTIVE: Retinopathy is an established microvascular complication of type 2 diabetes mellitus (T2DM), but its independent relationship with macrovascular and other microvascular complications is less well defined across the spectrum of kidney disease in T2DM. We examined the prognostic value of retinopathy in assessing the risk of developing end-stage renal disease (ESRD), cardiovascular morbidity or death among patients in the Trial to Reduce cardiovascular Events with Aranesp Therapy (TREAT)...
2014: BMJ Open Diabetes Research & Care
https://read.qxmd.com/read/25439107/-quipo-who-inject-epo
#22
MULTICENTER STUDY
Cécile Vigneau, Sylvie Le Stum, Corinne Isnard-Bagnis, Gabriel Choukroun, Yannick Lemeur, Nassim Kamar, Emmanuel Oger
INTRODUCTION: Erythropoiesis Stimulating Agents (ESA) are largely prescribed before dialysis stage to chronic kidney disease patients. In accordance to current international guidelines, lots have been made by pharmacological companies in order to improve self management of ESAs: subcutaneaous administration, pencil devices, mutidose cartridges, low injection volume, very fine needles, once a month injections but none is currently known on the percentage of patients who actually do self administration of ESAs...
December 2014: Néphrologie & Thérapeutique
https://read.qxmd.com/read/25239637/incidence-of-erythropoietin-antibody-mediated-pure-red-cell-aplasia-the-prospective-immunogenicity-surveillance-registry-prims
#23
MULTICENTER STUDY
Iain C Macdougall, Nicole Casadevall, Francesco Locatelli, Christian Combe, Gerard M London, Salvatore Di Paolo, Andreas Kribben, Danilo Fliser, Hans Messner, John McNeil, Paul Stevens, Antonio Santoro, Angel L M De Francisco, Paul Percheson, Anna Potamianou, Arnaud Foucher, Daniel Fife, Véronique Mérit, Els Vercammen
BACKGROUND: Subcutaneous administration of Eprex(®) (epoetin alfa) in patients with chronic kidney disease (CKD) was contraindicated in the European Union between 2002 and 2006 after increased reports of anti-erythropoietin antibody-mediated pure red cell aplasia (PRCA). The Prospective Immunogenicity Surveillance Registry (PRIMS) was conducted to estimate the incidence of antibody-mediated PRCA with subcutaneous administration of a new coated-stopper syringe presentation of Eprex(®) and to compare this with the PRCA incidence with subcutaneous NeoRecormon(®) (epoetin beta) and Aranesp(®) (darbepoetin alfa)...
March 2015: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/25011692/erythropoiesis-stimulating-agent-use-among-non-dialysis-dependent-ckd-patients-before-and-after-the-trial-to-reduce-cardiovascular-events-with-aranesp-therapy-treat-using-a-large-us-health-plan-database
#24
COMPARATIVE STUDY
Mae Thamer, Yi Zhang, Onkar Kshirsagar, Dennis J Cotter, James S Kaufman
BACKGROUND: In a landmark study, TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) examined the use of erythropoiesis-stimulating agent (ESA) therapy to treat anemia among patients with chronic kidney disease (CKD) and found no benefit compared to placebo. STUDY DESIGN: A retrospective observational design was used to determine the impact of TREAT on clinical practice. SETTING & PARTICIPANTS: A large US health plan database with more than 1...
November 2014: American Journal of Kidney Diseases
https://read.qxmd.com/read/24899820/reduction-of-costs-for-anemia-management-drugs-associated-with-the-use-of-ferric-citrate
#25
JOURNAL ARTICLE
Anila Thomas, Leif E Peterson
BACKGROUND: Ferric citrate is a novel phosphate binder which has the potential to reduce usage of erythropoietin-stimulating agents (ESAs) and intravenous (IV) iron used for anemia management during hemodialysis (HD) among patients with end-stage renal disease (ESRD). Currently, the potential health care cost savings on a national scale due to the use of ferric citrate in ESRD are undetermined. METHODS: Per-patient-per-year costs of ESAs (Epogen(®) and Aranesp(®) [Amgen Inc...
2014: International Journal of Nephrology and Renovascular Disease
https://read.qxmd.com/read/24448756/comparison-between-short-and-long-acting-erythropoiesis-stimulating-agents-in-hemodialysis-patients-target-hemoglobin-variability-and-outcome
#26
RANDOMIZED CONTROLLED TRIAL
Bassam Bernieh, Samra Abouchacra, Yousef Boobes, Mohammad R Al Hakim, Nico Nagelkerke, Ahmad Chaaban, Mohamad Ahmed, Qutaiba Hussain, Hanan El Jack, Faiz Abayechi, Imran Khan, Nicole Gebran
PURPOSE: Maintaining target hemoglobin (Hb) with minimal variability is a challenge in hemodialysis (HD) patients. The aim of this study is to compare the long- and short-acting erythropoietin-stimulating agents such as Aranesp and Eprex in achieving these targets. METHODS: Randomized, prospective, open-labeled study of 24 weeks includes stable patients on HD >3 months, age >18 years, and on Eprex for >3 months. Patients were randomized into two groups: A-(Aranesp group):HD patients on Eprex Q TIW or BIW were converted to Aranesp Q weekly, by using the conversion factor of 200:1 and those on Eprex Q weekly to Aranesp Q 2 weeks; B-(Eprex group):patients continued on Eprex treatment...
February 2014: International Urology and Nephrology
https://read.qxmd.com/read/24173670/dose-conversion-ratio-in-hemodialysis-patients-switched-from-darbepoetin-alfa-to-peg-epoetin-beta-affirm-study
#27
MULTICENTER STUDY
Peter Choi, Mourad Farouk, Nick Manamley, Janet Addison
INTRODUCTION: There is limited information published on switching erythropoiesis-stimulating agent (ESA) treatment for anemia associated with chronic kidney disease (CKD) from darbepoetin alfa (DA) to methoxy polyethylene glycol-epoetin beta (PEG-Epo) outside the protocol of interventional clinical studies. AFFIRM (Aranesp Efficiency Relative to Mircera) was a retrospective, multi-site, observational study designed to estimate the population mean maintenance dose conversion ratio [DCR; dose ratio achieving comparable hemoglobin level (Hb) between two evaluation periods] in European hemodialysis patients whose treatment was switched from DA to PEG-Epo...
November 2013: Advances in Therapy
https://read.qxmd.com/read/23982766/a-randomised-single-blind-study-to-improve-health-related-quality-of-life-by-treating-anaemia-of-chronic-kidney-disease-with-aranesp%C3%A2-darbepoetin-alfa-in-older-people-stimulate
#28
RANDOMIZED CONTROLLED TRIAL
Simon D Roger, Sarbjit V Jassal, Michael C Woodward, Steven Soroka, Lawrence P McMahon
BACKGROUND: The prevalence of chronic kidney disease (CKD) increases with age, and the risk of significant anaemia increases as renal function declines. The objectives of this study were to assess the effect of darbepoetin alfa administration on health-related quality of life (HRQOL) through treatment for anaemia in older patients with CKD. METHODS: In this multicentre, randomised, placebo-controlled trial, older patients (aged ≥ 70 years) with CKD (Stages 3-5, predialysis) and haemoglobin (Hb) < 11...
February 2014: International Urology and Nephrology
https://read.qxmd.com/read/23506972/a-single-center-prospective-randomized-controlled-trial-evaluating-the-safety-and-efficacy-of-intracoronary-erythropoietin-delivery-before-reperfusion-gauging-infarct-size-in-patients-with-acute-st-segment-elevation-myocardial-infarction-study-design-and-rationale
#29
JOURNAL ARTICLE
Jung-Won Suh, Yeonyee E Yoon, Il-Young Oh, Chang-Hwan Yoon, Young-Seok Cho, Tae-Jin Youn, In-Ho Chae, Dong-Ju Choi
BACKGROUND: Erythropoietin (EPO) protected the myocardium from ischemia and reperfusion injury in preclinical studies. However, whether EPO can reduce myocardial injury in patients with acute myocardial infarction (MI) is controversial. The inconsistent results of previous studies have been attributed to differences in the doses, timing, and routes of administration of EPO. In this study, we will evaluate intracoronary treatment with a long-acting EPO analog, darbepoetin-α, administered immediately before reperfusion in patients with acute anterior ST-segment elevation MI...
May 2013: Contemporary Clinical Trials
https://read.qxmd.com/read/23159232/hemoglobin-stability-in-patients-with-anemia-ckd-and-type-2-diabetes-an-analysis-of-the-treat-trial-to-reduce-cardiovascular-events-with-aranesp-therapy-placebo-arm
#30
RANDOMIZED CONTROLLED TRIAL
Hicham Skali, Julie Lin, Marc A Pfeffer, Chao-Yin Chen, Mark E Cooper, John J V McMurray, Allen R Nissenson, Giuseppe Remuzzi, Jerome Rossert, Patrick S Parfrey, Nairne W Scott-Douglas, Ajay K Singh, Robert Toto, Hajime Uno, Peter Ivanovich
BACKGROUND: Sparse data are available about the natural history of hemoglobin (Hb) level trends in contemporary patients with anemia, chronic kidney disease (CKD), and type 2 diabetes mellitus. We intended to describe Hb level trends over time with no or minimal administration of erythropoiesis-stimulating agents. STUDY DESIGN: Prospective clinical trial cohort. SETTING & PARTICIPANTS: 2,019 individuals with type 2 diabetes, moderate anemia, and CKD from the placebo arm of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) followed up for 2...
February 2013: American Journal of Kidney Diseases
https://read.qxmd.com/read/23095132/effect-of-ethnicity-on-erythropoietin-therapy-response-for-hemodialysis-patients-a-retrospective-study
#31
JOURNAL ARTICLE
Bader Al-Khalaf, Nour Al-Khalaf, Seham Mustafa
Anemia is a common feature in chronic kidney disease patients due to deficiency of erythropoietin (EPO). Diseased kidneys are unable to produce EPO, which enhances red blood cell production from the bone marrow. Recombinant human EPO in hemodialysis patients was introduced with perfect outcomes as a hormonal substitutive treatment. Some ethnic minority groups have high prevalence of anemia associated with chronic kidney diseases. The aim of this study is to evaluate the differences between African Caribbeans and Caucasians' EPO therapy response with regard to hemoglobin (Hb), some factors affecting it and some comorbid conditions...
October 2013: Hemodialysis International
https://read.qxmd.com/read/22997919/-long-acting-erythropoetin-efficacy-in-the-treatment-of-nephrogenic-anemia-in-patients-with-chronic-kidney-disease-during-predialysis-stage
#32
JOURNAL ARTICLE
Iu S Milovanov, L Iu Milovanova
AIM: Comparison of efficacy of 12-month treatment of anemia in patients with chronic kidney disease (CKD) of stage III - IV with a long-acting drug darbepoetin alpha - aranesp and short-acting drug erythropoietin beta - recormon. MATERIAL AND METHODS: A total of 44 patients with CKD of stage III-IVwere divided into two groups. Of them, 24 had chronic glomerulonephritis and 20 had tubulointerstitial nephritis with verified nephrogenic anemia. Group 1 consisted of 22 patients given long-acting erythropoetin (darbepoetin alpha) in an initial dose 0,75 mcg/kg each 2 weeks subcutaneously...
2012: Terapevticheskiĭ Arkhiv
https://read.qxmd.com/read/22644842/a-long-acting-erythropoietin-fused-with-noncytolytic-human-fc-for-the-treatment-of-anemia
#33
REVIEW
Se Hwan Yang, Sang In Yang, Yo-Kyung Chung
The Fc fusion technology has been introduced to generate long-acting antagonistic drugs such as Enbrel, Orencia and Amevive. Here, Genexine created a novel noncytolytic hybrid Fc (hyFc) as a carrier of agonistic protein drugs using naturally existing IgD and IgG4 Fcs without any mutation in the hyFc region. The erythropoietin (EPO) fused with hyFc exhibited little binding activity to FcγR and C1q molecules that are main mediators for death of target cells. The EPO-hyFc showed higher in vitro and in vivo bioactivities than EPOIgG1 Fc and highly glycosylated EPO (Aranesp)...
May 2012: Archives of Pharmacal Research
https://read.qxmd.com/read/22590483/comparative-cost-efficiency-across-the-european-g5-countries-of-originators-and-a-biosimilar-erythropoiesis-stimulating-agent-to-manage-chemotherapy-induced-anemia-in-patients-with-cancer
#34
JOURNAL ARTICLE
Matti Aapro, Paul Cornes, Diana Sun, Ivo Abraham
OBJECTIVES: To evaluate the comparative cost efficiency across the European Union G5 countries of the erythropoiesis-stimulating agents (ESAs) epoetin α (originator [Eprex®] and biosimilar [Binocrit®]; once weekly), epoetin β (NeoRecormon®; once weekly), and darbepoetin α (Aranesp®; once weekly or once every 3 weeks) under different scenarios of fixed and weight-based dosing in the management of chemotherapy-induced anemia. METHODS: Direct costs of ESA treatment were calculated for one patient with cancer undergoing chemotherapy (six cycles at 3-week intervals) with ESA initiated at week 4 and continued for 15 weeks...
May 2012: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/22526650/detection-of-recombinant-human-epo-administered-to-horses-using-maiia-lateral-flow-isoform-test
#35
JOURNAL ARTICLE
Maria Lönnberg, Ulf Bondesson, Florence Cormant, Patrice Garcia, Yves Bonnaire, Jan Carlsson, Marie-Agnes Popot, Niclas Rollborn, Kristina Råsbo, Ludovic Bailly-Chouriberry
Doping of horses with recombinant human erythropoietin (rHuEPO) to illegally enhance their endurance capacity in horseracing has been reported during the last years. This leads to increased blood viscosity which can result in sudden death and is of concern for the horse welfare. Additionally, the horse can start production of rHuEPO antibodies, which cross-reacts with endogenous equine EPO and can lead to severe anaemia and even death. In this study, a novel micro-chromatographic method, EPO WGA MAIIA, has been tested for the capability in plasma and urine samples to detect administration of erythropoiesis-stimulating agents, like the rHuEPO glycoprotein varieties Eprex and Aranesp, to horses...
June 2012: Analytical and Bioanalytical Chemistry
https://read.qxmd.com/read/22454833/a-new-analytical-method-based-on-anti-epo-monolith-column-and-lc-faims-ms-ms-for-the-detection-of-rhuepos-in-horse-plasma-and-urine-samples
#36
JOURNAL ARTICLE
Ludovic Bailly-Chouriberry, Florence Cormant, Patrice Garcia, Maria Lönnberg, Simon Szwandt, Ulf Bondesson, Marie-Agnès Popot, Yves Bonnaire
Recombinant human erythropoietin (rHuEPO) is a 30-34 kDa glycoprotein banned by the racing authorities. For some years this molecule has been detected in race horses in USA and in Europe, and even in racing camels. Although direct methods to differentiate horse endogenous EPO and rHuEPO have been developed either by LC-MS/MS or by isoelectric focusing (IEF) with double-blotting, the short confirmation time of such prohibited hormone in plasma remains a problem for horseracing doping control laboratories. In order to improve the rHuEPOs confirmation process in horse plasma or urine in terms of reliability and delay, a small anti-EPO monolith membrane contained in a disposable column (anti-EPO monolith column) has been successfully used and validated (n = 10)...
May 21, 2012: Analyst
https://read.qxmd.com/read/22187314/systematic-review-of-the-impact-of-erythropoiesis-stimulating-agents-on-fatigue-in-dialysis-patients
#37
JOURNAL ARTICLE
Kirsten L Johansen, Fredric O Finkelstein, Dennis A Revicki, Christopher Evans, Shaowei Wan, Matthew Gitlin, Irene L Agodoa
BACKGROUND: One of the cardinal symptoms of anemia in chronic kidney disease (CKD) patients is fatigue. Recently, results from Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) raised questions about the role of erythropoiesis-stimulating agents (ESAs) in improving fatigue and the appropriate hemoglobin (Hb) target in anemic patients with CKD. These discussions should be considered with all available evidence to determine the level of benefits and risks associated with ESA therapy on fatigue among both early-stage CKD patients and end-stage renal disease patients on dialysis...
June 2012: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/22184042/what-caused-excess-strokes-in-patients-randomized-to-darbepoetin-in-the-trial-to-reduce-cardiovascular-events-with-aranesp-therapy-treat-no-smoking-gun
#38
EDITORIAL
https://read.qxmd.com/read/22142701/erythropoietin-mimetic-compound-agem400-hes-binds-to-the-same-receptor-as-erythropoietin-but-displays-a-different-spectrum-of-activities
#39
JOURNAL ARTICLE
Claudia Kessler, Alexandra Greindl, Bettina Breuer, Udo Haberl, Andreas Rybka, Marco Emgenbroich, Hans-Georg Frank, Andy J G Pötgens
EPO mimetic peptides (EMPs) have a completely different structure than erythropoietin (EPO) or new generation recombinant erythropoiesis stimulating agents (ESAs) like Darbepoietin alfa (Aranesp) and continuous erythropoiesis stimulating agent (CERA). This study intended to compare the effects of a novel compound called AGEM400(HES), consisting of a dimeric EMP conjugated to hydroxyethyl starch (HES), to those of recombinant EPO. AGEM400(HES) efficiently stimulated erythropoiesis in vitro and efficiently stimulated survival of EPO-dependent cell line UT7/EPO...
February 2012: Cytokine
https://read.qxmd.com/read/22104547/stroke-in-patients-with-type-2-diabetes-mellitus-chronic-kidney-disease-and-anemia-treated-with-darbepoetin-alfa-the-trial-to-reduce-cardiovascular-events-with-aranesp-therapy-treat-experience
#40
RANDOMIZED CONTROLLED TRIAL
Hicham Skali, Hans-Henrik Parving, Patrick S Parfrey, Emmanuel A Burdmann, Eldrin F Lewis, Peter Ivanovich, Sai Ram Keithi-Reddy, Janet B McGill, John J V McMurray, Ajay K Singh, Scott D Solomon, Hajime Uno, Marc A Pfeffer
BACKGROUND: More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. We sought to identify baseline characteristics and postrandomization factors that might explain this association. METHODS AND RESULTS: A multivariate logistic regression model was used to identify baseline predictors of stroke in 4038 patients with diabetes mellitus, chronic kidney disease, and anemia randomized to receive darbepoetin alfa or placebo...
December 20, 2011: Circulation
keyword
keyword
76755
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.